The business development division was established in 1996 to introduce innovative and diversified products from renowned companies worldwide and to expand Orient Europharma’s overseas markets.
Licensing Department
The division’s licensing department actively searches for opportunities to obtain exclusive rights in Taiwan of internationally renowned products. Exclusive agreements in 2009 that the division has obtained for Taiwan and Southeast Asia include:
- An exclusive agreement with Italian pharmaceutical company Chiesi Farmaceutici to market Foster asthma medicine in Taiwan.
- An agreement with Japanese pharmaceutical company NanoCarrier Co. Ltd. for the exclusive marketing rights in Asia (excluding Japan) of Nanoplatin™, a new treatment for pancreatic cancer.
- Exclusive marketing rights in Taiwan from Japanese Senju Pharmaceutical Co. for non-steroidal, anti-inflammatory Bronuck ophthalmic solution, as well as Vido and Mytear over-the-counter ophthalmic solution product series.
- Exclusive marketing rights in Asia (excluding Japan) from U.S. biotech company Cel-Sci Corporation for Multikine, a product under development for the treatment of head and neck cancers.
- A license agreement with Korea-based Handok Pharmaceuticals Co. Ltd. for the exclusive distribution of Loramyc mucoadhesive buccal tablets in Taiwan, Singapore, and Malaysia.
- An agreement with U.S. pharmaceutical company Medinox to develop and market new anti-hypotensive drug NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia.
- A cooperation agreement with U.S. biopharmaceutical company AndroScience Corporation and exclusive rights to market ASC-J9 acne topical agent in Taiwan, Korea, Australia, New Zealand and Southeast Asia.
Overview of Licensing-in projects:
| Product Name | Company | Indication | Phase I | Phase II | Phase III | Registration |
Approval
|
|---|---|---|---|---|---|---|---|
| Foster | Chiesi | Asthma/COPD | |||||
| GluFast | Kissei | DM Type II | |||||
| Hylase | Riemser | Erase hyaluronate | |||||
| Loramyc | Handok | Oral Candidiasis | |||||
| Bronuck | Senju | NSAID | |||||
| VIDO/Mytear Series | Senju | Eyecare, OTC | |||||
| Ella | HRA Pharma | Contraceptive | |||||
| Multikine | CEL-SCI | Head & Neck Cancer | |||||
| Nanoplatin | NanoCarrier | Pancreatic Cancer | |||||
| NOX-100 | Medinox | Intradialytic Hypotension | |||||
| ASC-J9 | AndroScience | Acne |
For any enquiries, please contact : licensingin@mail.oep.com.tw
Licensing-out
Actively seeking strategic partners in Korea and Australia to collaborate in the development of Pancreatic Cancer drug, Nanoplatin and the new drug, Multikine for immune-based treatment of head and neck cancer.
For any enquiries, please contact : licensingout@mail.oep.com.tw